Loading…
← CockpitCompetitor Analysis › 300759.SZ Pharmaron Beijing Co., Ltd. Class AOpen in the cockpit ↗

Pharmaron Beijing Co., Ltd. Class A300759.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Leading contract research and manufacturing organization (CRO/CDMO) providing drug discovery and development services to global pharma.

≈ China's WuXi AppTec/Catalent hybridMomentum leader 96
Mkt cap
$9.90B
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$272M
20-day average traded
Fwd P/E
36.8×
forward earnings
ROIC−WACC
+1.3 pp
WACC 10.3%
Hurdle
n/a
no reverse DCF
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥40.41
1D-1.2%
1W-8.6%
1M+3.4%
3M-18.9%
6M+52.0%
YTD+42.1%
1Y+25.3%
ATR %6.5%
52w lowhigh24.6% off high

What Pharmaron Beijing does

Leading contract research and manufacturing organization (CRO/CDMO) providing drug discovery and development services to global pharma.

Is paid for services rather than for drugs: chemists billed by headcount for discovery work, and per project or batch for development and manufacturing. Clients are drugmakers that keep ownership of what is made, and US and European clients provide most of the revenue. Founder Lou Boliang is chairman.

In one line: China's WuXi AppTec/Catalent hybrid.

Products and services

  • Drug discovery services (CRO)
  • Process development/manufacturing (CDMO)
  • Clinical development services

Customers

  • Global pharma and biotech companies outsourcing R&

Where it sits in the supply chain

  • Pharmaceuticals services
  • CRO/CDMO
  • Drug discovery, development and…

What could go right

  • Global pharma R&D-outsourcing growth

What could go wrong

  • US/geopolitical biosecurity/outsourcing policy risk
  • Client R&D-spending cyclicality

Moat: narrow (scale, customer qualification, process know-how). Established global pharma-client relationships and integrated discovery-to-manufacturing service scale.

Headquarters: Beijing, China · Founded: 1996 · Employees: 25,088

Named competitors

Pharmaron Beijing at a glance

Size Pharmaron Beijing (300759.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $9.90B, the 241st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥40.41 on 18 Nov 2026.

Performance Over six months the shares gained 52.0%, against +7.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 18.2% over the last twelve months (peer median +13.3%); the operating margin is 14.4% (peer median 17.8%).

Valuation It trades at 36.8× forward earnings against a peer median of 32.0× (6th most expensive of 16).

Capital Return on invested capital runs 1.3 points above its cost of capital (10.3% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026300759.SZ 153Peer median 109
Six months, rebased to 100: Pharmaron Beijing against the median of its 20 peers (local-currency closes).

Pharmaron Beijing financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥16.0BCN¥14.1BCN¥12.3BCN¥11.5BCN¥10.3B
Revenue growth—+15%+7%+12%—
Gross profitCN¥6.24BCN¥4.60BCN¥4.15BCN¥3.86BCN¥3.56B
EBITDAn/aCN¥3.32BCN¥2.86BCN¥2.66BCN¥2.43B
Net incomeCN¥1.77BCN¥1.66BCN¥1.79BCN¥1.60BCN¥1.37B
Free cash flow-CN¥202MCN¥621MCN¥584M-CN¥62.3M-CN¥746M
Capital expenditureCN¥2.97BCN¥2.67BCN¥2.04BCN¥2.87BCN¥2.95B
Total debtCN¥7.47BCN¥7.04BCN¥5.98BCN¥9.70BCN¥6.14B

Quarterly statements and history in the cockpit →

Pharmaron Beijing competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%0%+20%TGTXSYREMDGLHLUN-ARGENPRAXMANKIND4151600436PTGX2607RYTMREC1177GLENMARKALK-BALKSDRREDDY2196ZYDUSLIFE300759.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Pharmaron Beijing is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×TGTXMDGLRGENMANKIND600436PTGX2607300759.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Pharmaron Beijing is the large dot.

Pharmaron Beijing competitors and peer comparison

Head to head with its named competitors (300759.SZ vs 2359.HK vs CRL vs LONN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Pharmaron Beijing 300759.SZ$9.90B+52%+18%14%36.8×n/a
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%

How Pharmaron Beijing compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pharmaron Beijing against its 20 peers (data as of 18 Nov 2026)
Measure300759.SZPeer medianRank in peer set
1-month return+3.4%+7.1%9th lowest of 21
6-month return+52.0%+7.3%4th highest of 21
Distance from 52-week high-24.6%-10.8%5th lowest of 21
Revenue growth (TTM)+18.2%+13.3%6th highest of 20
Operating margin14.4%17.8%8th lowest of 19
Forward P/E36.8×32.0×6th most expensive of 16
ROIC minus cost of capital+1.3 pp+1.4 pp10th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Pharmaron Beijing 300759.SZChina$9.90B+52%+18%14%36.8×n/an/a
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%25.2×43.0%+426.7%
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Repligen RGENUnited States$11.0B+55%+14%9%71.0×56.9%+15.0%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%6.3×-9.7%+7.4%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%9.0×19.9%+5.8%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a

Questions

Who are Pharmaron Beijing's main competitors?
Named competitors: WuXi AppTec (2359.HK), Charles River Laboratories (CRL), Lonza Group (LONN.SW), Catalent (private or unlisted). The cockpit's measured peer set (industry) also includes TG Therapeutics (TGTX), Spyre Therapeutics (SYRE), Madrigal Pharmaceuticals (MDGL), H. Lundbeck A/S (HLUN-A.CO), Repligen (RGEN), Praxis Precision Medicines (PRAX).
Is Pharmaron Beijing expensive compared with its peers?
On forward p/e it trades at 36.8× against a peer median of 32.0×, 6th most expensive of 16 in its peer set.
How has Pharmaron Beijing stock performed?
Over six months to 18 Nov 2026 the shares returned +52.0% against +7.3% for the median peer; over one year +25.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.